TAI •
Healthcare •
Biotechnology •
Quote as of 07/27/2026 13:30
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTAI
Market Capitalization4,143.81 mln
Float102 mln
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.84
Likely reliable
Relative Strength
83
/ 100
Strongly outperforming
Debt / Equity
0.13
Very low leverage
ROE
-5.12
Negative
Dividend Yield
0.00%
No dividend
Business Description
StemCyte International Ltd. is a biotechnology company founded in 1997 and headquartered in Taipei, Taiwan, that operates cord blood banks and develops cell-based treatments across the United States and Taiwan. Its lead product, REGENECYTE, uses donated umbilical cord blood to treat a range of serious conditions including cancer, blood disorders, immune diseases, stroke, and cerebral palsy. The company is also advancing CB201, an early-stage therapy targeting blood cancers, and operates as a subsidiary of Diamond Biofund Inc.
